Japan clears IMCIVREE for acquired hypothalamic obesity as Rhythm Pharmaceuticals expands global reach
Japan approves IMCIVREE for acquired hypothalamic obesity, expanding Rhythm Pharmaceuticals’ global franchise. See what the approval means for growth.